Crescent Biopharma, Inc. (CBIO)
CBIONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$13.65
+0.1100 (+0.81%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $507.01m
- P/E
- –
- EPS, last 4 quarters
- $-6.72
- Dividend yield
- –
- Day range
- –
- 52-week range
- $8.72 to $27.41
- Average volume
- 388.5k
- Previous close
- $13.54
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $30.80, +125.6% from here
Earnings
next estimate $-0.7200Next report
Sep 2025
-25.7%
Dec 2025
-80.6%
Mar 2026
+17.6%
Jun 2026
+5.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | $10.84m | $1.04m | – |
| Gross profit | – | $10.84m | $1.04m | – |
| Operating income | -$25.89m | -$91.49m | -$24.73m | -$26.36m |
| Net income | -$24.61m | -$92.40m | -$23.28m | -$24.84m |
News
8 latest- HC Wainwright & Co. Upgrades Crescent Biopharma to Buy from NeutralFintel · Oct 6, 2026
- Crescent Biopharma Gets FDA Clearance For Next-Gen Cancer ADC CR-002 RTTNews · Oct 5, 2026
- Crescent Biopharma In Focus Ahead Of September Conferences And Key Catalysts RTTNews · Sep 8, 2026
- Crescent Biopharma Prices $125 Mln Offering Of Shares And Pre-funded Warrants; Stock Down RTTNews · Jul 15, 2026
- Crescent Biopharma (CBIO) Price Target Increased by 10.69% to 29.92Fintel · Feb 3, 2026
- Guggenheim Initiates Coverage of Crescent Biopharma (CBIO) with Buy RecommendationFintel · Jan 21, 2026
- Crescent Biopharma Secures IND Clearances For Two Novel Oncology Candidates RTTNews · Jan 5, 2026
- Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up RTTNews · Dec 4, 2025
The company
Crescent Biopharma's vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company's clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- crescentbiopharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.